Author's response to reviews

Title: Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease

Authors:

Christine Jenkins (christine.jenkins@sydney.edu.au)
Dirkje S Postma (d.s.postma@umcg.nl)
Antonio R Anzueto (anzueto@uthscsa.edu)
Barry J Make (makeb@njhealth.org)
Stefan Peterson (stefan.peterson@astrazeneca.com)
Göran Eriksson (goran.s.eriksson@astrazeneca.com)
Peter M Calverley (pmacal@liverpool.ac.uk)

Version: 2
Date: 15 October 2014

Author's response to reviews:

1) Line numbers have been added on each page, as requested.

2) Please note that this manuscript describes a post-hoc, retrospective analysis of the Sharafkhaneh et al. clinical trial (NCT00419744, http://www.ncbi.nlm.nih.gov/pubmed/22033040). All the available details for the Institutional review board approval and GCP are taken from the previously-published manuscript; therefore, we have not added which IRB approved the previous clinical trial. Please let me know if this is a problem.